Related Experiment Video
Updated: Mar 21, 2026

Development of Human Renal Tubular Epithelial Cell Primary Cultures in Monolayers and Three-Dimensional Conditions
Published on: June 13, 2025
An evaluation of the antioxidant protein α1-microglobulin as a renal tubular cytoprotectant
Richard A Zager1, Ali C M Johnson2, Kirsten Frostad2
1Fred Hutchinson Cancer Center, Seattle, Washington; and University of Washington, Seattle Washington dzager@fredhutch.org.
Abstract:
α1-Microglobulin (A1M) is a low-molecular-weight heme-binding antioxidant protein that is readily filtered by the glomerulus and reabsorbed by proximal tubules. Given these properties, recombinant A1M (rA1M) has been proposed as a renal antioxidant and therapeutic agent. However, little direct evidence to support this hypothesis exists. Hence, we have sought "proof of concept" in this regard. Cultured proximal tubule (HK-2) cells or isolated mouse proximal tubule segments were challenged with a variety of prooxidant insults: 1) hemin, 2) myoglobin; 3) "catalytic" iron, 4) H2O2/Fenton reagents, 5) a Ca(2+) ionophore, 6) antimycin A, or 7) hypoxia (with or without rA1M treatment). HK-2 injury was gauged by the percent lactate dehydrogenase release and 4,5-(dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide uptake. In vivo protection was sought in rA1M-treated mice subjected to 1) graded myohemoglobinura (2, 4, 8, or 9 ml/kg glycerol injection), 2) purified myoglobinemia/uria, or 3) endotoxemia. In vivo injury was assessed by blood urea nitrogen, creatinine, and the expression of redox-sensitive genes (heme oxygenase-1, neutrophil gelatinase-associated lipocalin, and monocyte chemoattractant protein-1 mRNAs). Although rA1M totally blocked in vitro hemin toxicity, equimolar albumin (another heme binder) or 10% serum induced equal protection. rA1M failed to mitigate any nonhemin forms of either in vitro or in vivo injury. A1M appeared to be rapidly degraded within proximal tubules (by Western blot analysis). Surprisingly, rA1M exerted select injury-promoting effects (increased in vitro catalytic iron/antimycin toxicities and increased in vivo monocyte chemoattractant protein-1/neutrophil gelatinase-associated lipocalin mRNA expression after glycerol or endotoxin injection). We conclude that rA1M has questionable utility as a renal antioxidant/cytoprotective agent, particularly in the presence of larger amounts of competitive free heme (e.g., albumin) binders.
Insights
Recombinant alpha1-microglobulin (rA1M) showed limited renal antioxidant effects, failing to protect against most prooxidant injuries and even worsening some. Its utility as a renal therapeutic agent is questionable, especially with competing heme binders present.
Area of Science:
- Nephrology
- Biochemistry
- Oxidative Stress Research
Background:
- Alpha1-microglobulin (A1M) is a heme-binding protein filtered and reabsorbed by renal proximal tubules.
- Recombinant A1M (rA1M) has been proposed as a potential renal antioxidant and therapeutic agent.
- Direct evidence supporting rA1M's efficacy in renal protection is limited.
Purpose of the Study:
- To investigate the "proof of concept" for recombinant A1M (rA1M) as a renal antioxidant and cytoprotective agent.
- To evaluate rA1M's protective effects against various in vitro and in vivo prooxidant insults in the kidney.
Main Methods:
- In vitro studies utilized cultured human proximal tubule (HK-2) cells and isolated mouse proximal tubule segments exposed to prooxidants (hemin, myoglobin, catalytic iron, H2O2, Ca(2+) ionophore, antimycin A, hypoxia) with or without rA1M.
- In vivo studies involved rA1M-treated mice subjected to myohemoglobinuria (glycerol injection), myoglobinemia/uria, or endotoxemia.
- Cellular injury was assessed by lactate dehydrogenase release and MTT assay; kidney injury was evaluated by blood urea nitrogen, creatinine, and gene expression (HO-1, NGAL, MCP-1).
Main Results:
- rA1M completely blocked in vitro hemin toxicity, but equimolar albumin or serum provided similar protection, suggesting non-specific binding.
- rA1M failed to mitigate injury from non-hemin prooxidants in vitro or in vivo.
- Surprisingly, rA1M exacerbated certain in vitro toxicities and upregulated pro-inflammatory genes (MCP-1, NGAL) in vivo following glycerol or endotoxin challenge.
Conclusions:
- Recombinant A1M (rA1M) demonstrates questionable utility as a renal antioxidant and cytoprotective agent.
- Its efficacy is limited, particularly in the presence of abundant competing heme-binding proteins like albumin.
- rA1M may possess unexpected injury-promoting effects in specific renal prooxidant conditions.
Related Concept Videos
Renal Drug Excretion: Tubular Secretion
Drug Elimination by Renal Route: Tubular Secretion
Drug Elimination by Renal Route: Tubular Reabsorption
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Renal Drug Excretion: Tubular Reabsorption

